GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyundai Bioscience Co Ltd (XKRX:048410) » Definitions » Debt-to-Revenue

Hyundai Bioscience Co (XKRX:048410) Debt-to-Revenue : 0.27 (As of Mar. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Hyundai Bioscience Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Hyundai Bioscience Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩5,510 Mil. Hyundai Bioscience Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩24 Mil. Hyundai Bioscience Co's annualized Revenue for the quarter that ended in Mar. 2024 was ₩20,199 Mil. Hyundai Bioscience Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.27.


Hyundai Bioscience Co Debt-to-Revenue Historical Data

The historical data trend for Hyundai Bioscience Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyundai Bioscience Co Debt-to-Revenue Chart

Hyundai Bioscience Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 2.97 1.68 0.80 0.59

Hyundai Bioscience Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.43 0.76 1.22 0.27

Competitive Comparison of Hyundai Bioscience Co's Debt-to-Revenue

For the Biotechnology subindustry, Hyundai Bioscience Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyundai Bioscience Co's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyundai Bioscience Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Hyundai Bioscience Co's Debt-to-Revenue falls into.



Hyundai Bioscience Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Hyundai Bioscience Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(5514.103 + 32.432) / 9481.385
=0.58

Hyundai Bioscience Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(5509.538 + 24.159) / 20199.096
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Hyundai Bioscience Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hyundai Bioscience Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyundai Bioscience Co (XKRX:048410) Business Description

Traded in Other Exchanges
N/A
Address
150 North-Ahyun Road, 3rd Floor Academic Cooperation Building, Ehwa Women’s University, Seodaemun-gu, Seoul, KOR
Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand.

Hyundai Bioscience Co (XKRX:048410) Headlines

No Headlines